Polar Capital Holdings PLC Alkermes Plc. Transaction History

Polar Capital Holdings PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$27.17 - $31.97 $40.8 Million - $48 Million	-1,500,000 Reduced 51.94%	1,388,016 $38.9 Million
Q1 2023 Dec 13, 2023	BUY	$25.31 - $29.02 $38 Million - $43.5 Million	1,500,000 Added 108.07%	2,888,016 $81.4 Million
Q1 2023 May 15, 2023	BUY	$25.31 - $29.02 $16.1 Million - $18.5 Million	636,574 Added 28.27%	2,888,016 $81.4 Million
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $21.6 Million - $25.8 Million	984,246 Added 77.67%	2,251,442 $58.8 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $27.9 Million - $40.4 Million	1,267,196 New	1,267,196 $28.3 Million

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.88B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Polar Capital Holdings PLC with notifications on news.